ACM
ALLO icon

Advisors Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Advisors Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Buy
+11,002
New +$24.2K ﹤0.01% 634

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Advisors Capital Management's ALLO Position: Q2 2026 in Review

Advisors Capital Management opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 11,002 shares worth $22.9K. The stake represents ﹤0.01% of the portfolio and ranks #634 among its holdings.

209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Advisors Capital Management held 11,002 shares of Allogene Therapeutics worth $22.9K as of Q2 2026.
  • Allogene Therapeutics was a new Advisors Capital Management position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Advisors Capital Management's portfolio in Q2 2026, its #634 holding.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.